Rallybio to merge with Avenzo Therapeutics via reverse merger backed by $215M private placement, combined company to be renamed Avenzo Therapeutics (AVZO)
- Current Rallybio shareholders will receive a distribution of substantially all pre-closing net cash.
- They will also receive contingent value rights on legacy assets and approximately 2.8% of the combined company.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.